Advancing Treatments for Bladder Cancer: Insights from ASCO GU 2024 - Episode 8

Later-Line Therapies for Metastatic Urothelial Carcinoma

, , ,

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

EP. 1: Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)
EP. 2: Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer
EP. 3: Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
EP. 4: Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer
EP. 5: Emerging Data in Metastatic Urothelial Carcinoma
EP. 6: Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma
EP. 7: Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma
Now Viewing
EP. 8: Later-Line Therapies for Metastatic Urothelial Carcinoma
EP. 9: Treatment Sequencing Practices in Metastatic Urothelial Carcinoma
EP. 10: Exciting New Approaches in Metastatic Urothelial Carcinoma
EP. 11: Key Takeaways on Updates in Bladder Cancer

Related Content:

Advancing Treatments for Bladder Cancer: Insights from ASCO GU 2024Fox Chase Cancer CenterHuntsman Cancer Institute at the University of Utah University of North Carolina, Lineberger Comprehensive Cancer CenterFred Hutch Cancer CenterGenitourinary CancersOncLive Peer Exchange®
Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNA
NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs
Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents